Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CAR-T Technology for the Treatment of Recurrent/Refractory Malignant Hematological and Lymphatic Tumors: Multi-Center Clinical Study on Safety and Efficacy

NCT06647329 is registered in ClinicalTrials.gov with Mingzhi Zhang as lead sponsor.

NCT NCT06647329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06647329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CAR-T Technology for the Treatment of Recurrent/Refractory Malignant Hematological and Lymphatic Tumors: Multi-Center Clinical Study on Safety and Efficacy
Lead sponsor
Mingzhi Zhang
Phase
Phase 1
Overall status
Not yet recruiting
Start date
December 1, 2024
Completion date
December 31, 2026
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

car-t cell therapy, lymphomas